Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC

Conditions

• Esophageal Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Adebrelimab — DRUG
  anti-PD-L1 immunotherapy
• Nab paclitaxel — DRUG
  chemotherapy
• Carboplatin — DRUG
  chemotherapy
• radiation — RADIATION
  radiation

Study Details

A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups. Arm A: After 2 cycles of induction adebrelimab plus chemotherapy, patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f), and adebrelimab will maintain to PD or for a maximum of 15 cycles. Arm B: Patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f) and adebrelimab will maintain to PD or for a maximum of 17 cycles. This study will compare the efficacy of immunotherapy in the induction and maintenance phases of radiotherapy, optimize more precise treatment plans, and potentially further increase the survival of ESCC patients.

Key Dates

First listed

Jul 29, 2026

Start date

Jul 31, 2026

Status verified

Jul 2026

Primary completion

Dec 31, 2027

Completion

Dec 31, 2029

Study Design

Enrollment

120 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A
  Induction Immunochemotherapy + CRT 1. Induction immunochemotherapy: Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22. 2. Concurrent chemoradiotherapy: Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f. 3. Immunotherapy maintenance: Adebrelimab：1200mg, IV，q3w, until PD or for a maximum of 15 cycles.
• Experimental: Arm B
  CRT + Immunotherapy 1. Concurrent chemoradiotherapy: Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f. 2. Immunotherapy maintenance: Adebrelimab：1200mg, IV，q3w, until PD or for a maximum of 17 cycles.

Primary Outcome Measure

Progression-free survival [ Time Frame: From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months. ]

Central Contacts

• Wencheng Zhang, MD
  02223340123
  [email protected]

Find similar trials

Related Studies

• Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Esophageal Cancer Risk Registry
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
  Recruiting · University of Colorado, Denver · Aurora, Colorado